Zezhi He, Jiazhen Chen, Hui Wu, Haojia Shen, Runxiang Li
{"title":"探究慢性荨麻疹发病机制的编码:ceRNA网络如何调控肥大细胞活化。","authors":"Zezhi He, Jiazhen Chen, Hui Wu, Haojia Shen, Runxiang Li","doi":"10.1159/000547368","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic urticaria (CU) is an inflammatory skin disease characterized by aberrant mast cell (MC) activation. Notably, 30% of patients show poor response to existing therapies. The competitive endogenous RNA (ceRNA) network has emerged as a key regulator of MC signaling, but the hierarchical regulatory mechanisms underlying this process remain incompletely understood.</p><p><strong>Summary: </strong>This review systematically analyzed PubMed and Web of Science literature (2000-2024) using keywords linking CU, ceRNA/long-stranded non-coding RNA/circular RNA, and MCs. It proposes a three-tiered regulatory model of the ceRNA network in maintaining sustained MC activation: (1) core RNAs (e.g., NEAT1) adsorb microRNAs (miRNAs) to deregulate key signaling pathways; (2) shared miRNAs (e.g., miR-155) act as bridges between upstream and downstream targets; and (3) effector molecules (e.g., STAT3) drive MC activation. RNA-based therapeutics and exosome delivery technologies targeting these regulatory axes may offer new strategies for refractory CU.</p><p><strong>Key messages: </strong>(1) The ceRNA network orchestrates MC activation through hierarchical regulation of core RNAs, shared miRNAs, and effector molecules. (2) Targeting ceRNA-mediated pathways holds promise for developing precision therapies for CU, particularly in patients unresponsive to conventional treatments. (3) Translational approaches using RNA therapeutics or exosome systems may address therapeutic gaps in refractory cases.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Probing the Code of Chronic Urticaria Pathogenesis: How the ceRNA Network Regulates Mast Cell Activation.\",\"authors\":\"Zezhi He, Jiazhen Chen, Hui Wu, Haojia Shen, Runxiang Li\",\"doi\":\"10.1159/000547368\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chronic urticaria (CU) is an inflammatory skin disease characterized by aberrant mast cell (MC) activation. Notably, 30% of patients show poor response to existing therapies. The competitive endogenous RNA (ceRNA) network has emerged as a key regulator of MC signaling, but the hierarchical regulatory mechanisms underlying this process remain incompletely understood.</p><p><strong>Summary: </strong>This review systematically analyzed PubMed and Web of Science literature (2000-2024) using keywords linking CU, ceRNA/long-stranded non-coding RNA/circular RNA, and MCs. It proposes a three-tiered regulatory model of the ceRNA network in maintaining sustained MC activation: (1) core RNAs (e.g., NEAT1) adsorb microRNAs (miRNAs) to deregulate key signaling pathways; (2) shared miRNAs (e.g., miR-155) act as bridges between upstream and downstream targets; and (3) effector molecules (e.g., STAT3) drive MC activation. RNA-based therapeutics and exosome delivery technologies targeting these regulatory axes may offer new strategies for refractory CU.</p><p><strong>Key messages: </strong>(1) The ceRNA network orchestrates MC activation through hierarchical regulation of core RNAs, shared miRNAs, and effector molecules. (2) Targeting ceRNA-mediated pathways holds promise for developing precision therapies for CU, particularly in patients unresponsive to conventional treatments. (3) Translational approaches using RNA therapeutics or exosome systems may address therapeutic gaps in refractory cases.</p>\",\"PeriodicalId\":13652,\"journal\":{\"name\":\"International Archives of Allergy and Immunology\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Archives of Allergy and Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547368\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547368","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:慢性荨麻疹(CU)是一种由肥大细胞(MC)异常活化引起的炎症性皮肤病,但30%的患者对现有治疗反应不佳。近年来研究发现竞争性内源性RNA (ceRNA)网络是调节肥大细胞信号传导的关键机制,但其分级调控的具体机制尚未完全阐明。本综述旨在分析ceRNA网络在维持肥大细胞持续激活中的作用,提出一个三层调控模型,并评估其转化为精确治疗的策略。方法使用关键词(“慢性荨麻疹”和(“ceRNA”或“lncRNA”或“circRNA”)和(“肥大细胞”))进行系统的PubMed/Web of Science分析(2000-2024),整合了ceRNA通路机制,并通过GDP建立了基于证据的原理图。结论ceRNA网络通过三个层次的分级调控发挥作用:(1)核心rna(如NEAT1)吸附mirna,解除对关键信号通路的调控;(2)共享mirna(如miR-155)连接上下游靶点;(3)效应分子(如STAT3)驱动肥大细胞活化。RNA疗法或靶向这些轴的外泌体递送技术有望为难治性CSU提供新的策略。
Probing the Code of Chronic Urticaria Pathogenesis: How the ceRNA Network Regulates Mast Cell Activation.
Background: Chronic urticaria (CU) is an inflammatory skin disease characterized by aberrant mast cell (MC) activation. Notably, 30% of patients show poor response to existing therapies. The competitive endogenous RNA (ceRNA) network has emerged as a key regulator of MC signaling, but the hierarchical regulatory mechanisms underlying this process remain incompletely understood.
Summary: This review systematically analyzed PubMed and Web of Science literature (2000-2024) using keywords linking CU, ceRNA/long-stranded non-coding RNA/circular RNA, and MCs. It proposes a three-tiered regulatory model of the ceRNA network in maintaining sustained MC activation: (1) core RNAs (e.g., NEAT1) adsorb microRNAs (miRNAs) to deregulate key signaling pathways; (2) shared miRNAs (e.g., miR-155) act as bridges between upstream and downstream targets; and (3) effector molecules (e.g., STAT3) drive MC activation. RNA-based therapeutics and exosome delivery technologies targeting these regulatory axes may offer new strategies for refractory CU.
Key messages: (1) The ceRNA network orchestrates MC activation through hierarchical regulation of core RNAs, shared miRNAs, and effector molecules. (2) Targeting ceRNA-mediated pathways holds promise for developing precision therapies for CU, particularly in patients unresponsive to conventional treatments. (3) Translational approaches using RNA therapeutics or exosome systems may address therapeutic gaps in refractory cases.
期刊介绍:
''International Archives of Allergy and Immunology'' provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases.